SURPASS trial programme (revision 4)
Old revision·08:48, 13 Aug 2024·LOD_Lorcan
| SURPASS trial programme | |
|---|---|
| Drug | Tirzepatide 5, 10 and 15 mg weekly |
| Indication | Type 2 diabetes |
| Notable member | SURPASS-2, head-to-head with semaglutide |
| Topic infobox · conventions | |
The SURPASS trial programme is the phase 3 series that established tirzepatide for type 2 diabetes. Its trials compared tirzepatide at 5, 10 and 15 mg weekly against placebo, semaglutide 1 mg, insulin degludec, insulin glargine and dulaglutide.[1]
Glycated-haemoglobin reductions across the programme were larger than those reported for any comparator, reaching about 2.0–2.6 percentage points at the higher doses depending on trial and baseline. Weight reduction accompanied them at every dose.[1]
Constituent trials
[edit]| Trial | Comparator | Notes |
|---|---|---|
| SURPASS-1 | Placebo | Monotherapy in drug-naive participants |
| SURPASS-2 | Semaglutide 1 mg | Open-label head-to-head |
| SURPASS-3 | Insulin degludec | Added to metformin ± SGLT2 inhibitor |
| SURPASS-4 | Insulin glargine | High cardiovascular risk population |
| SURPASS-5 | Placebo | Added to insulin glargine |
| SURPASS-CVOT | Dulaglutide | Cardiovascular outcomes, active comparator |
SURPASS-CVOT is unusual among cardiovascular outcome trials in using an active comparator with an established benefit rather than placebo, which changes what a non-inferiority result means: non-inferiority to an agent that itself reduced events is a stronger statement than non-inferiority to placebo.[1]